CRIS Current Research Information System

CATTINA, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.723
AS - Asia 2.493
EU - Europa 2.078
AF - Africa 171
SA - Sud America 139
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.611
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.694
SG - Singapore 706
CN - Cina 657
GB - Regno Unito 599
VN - Vietnam 589
SE - Svezia 356
DE - Germania 266
IT - Italia 194
HK - Hong Kong 190
FR - Francia 151
IN - India 138
RU - Federazione Russa 114
BR - Brasile 90
IE - Irlanda 79
NL - Olanda 72
CH - Svizzera 57
ZA - Sudafrica 56
TG - Togo 44
EE - Estonia 42
JP - Giappone 38
NG - Nigeria 37
FI - Finlandia 32
UA - Ucraina 31
AR - Argentina 26
PH - Filippine 21
BG - Bulgaria 19
CA - Canada 19
GR - Grecia 18
JO - Giordania 18
CI - Costa d'Avorio 17
IR - Iran 17
BE - Belgio 16
KR - Corea 16
IQ - Iraq 15
TH - Thailandia 12
BD - Bangladesh 11
TR - Turchia 11
TW - Taiwan 9
AT - Austria 8
MX - Messico 8
ES - Italia 7
LB - Libano 7
UZ - Uzbekistan 7
ID - Indonesia 6
PK - Pakistan 6
PL - Polonia 6
SA - Arabia Saudita 6
AU - Australia 5
CL - Cile 5
CO - Colombia 4
CZ - Repubblica Ceca 4
EG - Egitto 4
KZ - Kazakistan 4
SC - Seychelles 4
AE - Emirati Arabi Uniti 3
EC - Ecuador 3
PY - Paraguay 3
VE - Venezuela 3
GY - Guiana 2
MA - Marocco 2
OM - Oman 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
KE - Kenya 1
MK - Macedonia 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
ZW - Zimbabwe 1
Totale 7.611
Salva come PNG Salva come JPEG
Città #
Southend 549
Singapore 485
Ashburn 288
Chandler 288
Fairfield 230
Hong Kong 181
Beijing 142
Ho Chi Minh City 136
Houston 135
Ann Arbor 129
San Jose 120
Seattle 120
Wilmington 119
Hanoi 116
Woodbridge 112
Princeton 110
Santa Clara 97
Dublin 79
Dong Ket 76
Cambridge 74
Boardman 63
Lauterbourg 55
Nanjing 53
Bern 51
Westminster 50
Padova 49
Lomé 44
Medford 41
Bologna 38
Los Angeles 38
Tokyo 35
New York 34
Helsinki 26
Frankfurt am Main 25
Hebei 25
Abeokuta 24
Hefei 24
Jinan 24
Shenyang 24
Saint Petersburg 23
Haiphong 20
Nanchang 20
Redondo Beach 20
Shanghai 20
Changsha 19
Amman 18
Berlin 18
San Diego 18
Sofia 18
São Paulo 18
Abidjan 17
Bremen 16
Brussels 16
Florence 16
Tianjin 16
Da Nang 15
Guangzhou 14
Turin 13
Buffalo 12
Dallas 12
Falls Church 12
Hangzhou 10
Ningbo 10
Jiaxing 9
Milan 9
Munich 9
Norwalk 9
Seoul 9
Hải Dương 8
Mountain View 8
Paris 8
Redwood City 8
Johannesburg 7
London 7
Toronto 7
Baghdad 6
Brooklyn 6
Can Tho 6
Dearborn 6
Düsseldorf 6
Fuzhou 6
Hyderabad 6
Lanzhou 6
Las Vegas 6
Tehran 6
Xi'an 6
Zhengzhou 6
Amsterdam 5
Bangkok 5
Haikou 5
Kunming 5
Manila 5
Mashhad 5
Mumbai 5
Mülheim 5
Nuremberg 5
Orem 5
Phoenix 5
Roubaix 5
Taiyuan 5
Totale 4.935
Salva come PNG Salva come JPEG
Nome #
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 251
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 233
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 226
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 219
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 210
RALE051: a novel established cell line of sporadic Burkitt lymphoma 209
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 209
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 207
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 200
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 188
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 185
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 185
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 184
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 172
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 172
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 171
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 168
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 165
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 163
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 162
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 161
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 159
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 159
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 158
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 157
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 157
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 157
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 156
NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING TECHNOLOGY REVEALS NOVEL COMMON GENETIC ALTERATIONS IN THE HEDGEHOG PATHWAY IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 154
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 154
MULTIPLEX PCR TO RAPIDLY IDENTIFY IKZF1 (IKAROS) GENE BREAKPOINTS IN BCRABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 147
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 143
LOSS OF CDKN2A GENE IS A POOR PROGNOSTIC MARKER IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS 142
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 141
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 140
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 138
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 138
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) 135
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 134
The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma 133
The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL) 131
Molecular characterization of TP53 mutations in B-acute lymphoblastic leukemia (B-ALL) reveals missense substitutions, aberrant exon-junctions and intron retention events 125
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies 125
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 125
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 115
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 108
Loss of the tumor suppressor genes CDKN2A/ARF impairs prognosis in adult BCR-ABL1 positive acute lymphoblastic leukemia (ALL) 106
PROSPECTIVE PHASE II STUDY ON LOW-DOSE 5-AZACYTIDINE FOR TREATMENT OF SYMPTOMATIC PATIENTS WITH LOW/INT-1 RISK MYELODISPLASIA 67
Totale 7.744
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.470
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.470
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021261 0 0 0 0 0 0 0 0 0 35 43 183
2021/2022912 64 13 64 67 106 69 13 48 46 78 156 188
2022/20231.177 168 190 42 156 85 89 31 75 160 14 81 86
2023/2024269 13 49 8 30 16 56 19 16 19 12 11 20
2024/2025981 55 170 88 70 152 35 59 12 13 106 14 207
2025/20262.081 154 151 169 125 280 132 228 98 565 179 0 0
Totale 7.744